GE HealthCare announces five new global collaborations to advance the next generation of theranostics imaging
Key Highlights
- ➤Five institutions across three continents will evaluate GE HealthCare’s StarGuide GX 4D SPECT/CT system
- ➤More than 1,000 patients scanned across the global clinical evaluation program
- ➤StarGuide GX received CE Mark in November 2025 and is available in select EU states
- ➤U.S. FDA 510(k) remains pending; StarGuide GX is not available for U.S. sale
- ➤Low-Medium Energy collimator designed to provide up to 2.67-times system volume sensitivity
Expert Statements
Erez Levy, Executive Director, Molecular Imaging, GE HealthCare
“Nuclear medicine is entering a new era in which imaging is expected to do more than identify disease – it is increasingly being used to quantify biological processes, support treatment decisions and monitor response to therapy.”
Erez Levy, Executive Director, Molecular Imaging, GE HealthCare
“By working across multiple regions and care environments, we aim to generate clinical and research insights that can help inform innovation as imaging, quantitation and workflow needs evolve.”
Frederic Courbon, Head of the Imaging Department, Oncopole Claudius Regaud – Institut Universitaire du Cancer de Toulouse
“The technological innovations introduced by StarGuide GX are particularly exciting for the future of theranostics.”
Frederic Courbon, Head of the Imaging Department, Oncopole Claudius Regaud – Institut Universitaire du Cancer de Toulouse
“The system's ergonomic design and flexibility have the potential to significantly improve workflow while supporting precision in quantitative imaging and high-energy radionuclide applications.”
Frederic Courbon, Head of the Imaging Department, Oncopole Claudius Regaud – Institut Universitaire du Cancer de Toulouse
“Our first experience suggests that StarGuide GX represents a meaningful step forward in enabling advanced theranostic practices.”
GE HealthCare announces five new global collaborations to advance the next generation of theranostics imaging
* Leading institutions will evaluate StarGuide GX(i) across quantitative imaging, dynamic imaging and emerging theranostic applications
Get started
Create a free account to read the full story.